Q2 Earnings Estimate for MLTX Issued By Leerink Partnrs

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for shares of MoonLake Immunotherapeutics in a report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($0.82) for the quarter. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics’ Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.78) EPS and FY2029 earnings at $7.54 EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09).

A number of other brokerages also recently commented on MLTX. Needham & Company LLC lifted their price objective on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday. Wedbush reaffirmed an “outperform” rating and set a $73.00 target price (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. The Goldman Sachs Group reduced their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a report on Thursday. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $83.20.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX opened at $41.76 on Friday. The firm has a 50-day moving average of $46.70 and a 200-day moving average of $48.94. MoonLake Immunotherapeutics has a one year low of $37.55 and a one year high of $58.26. The company has a market cap of $2.67 billion, a PE ratio of -32.37 and a beta of 1.28.

Institutional Trading of MoonLake Immunotherapeutics

A number of institutional investors have recently bought and sold shares of the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in MoonLake Immunotherapeutics in the 4th quarter valued at about $1,091,000. Jefferies Financial Group Inc. acquired a new position in shares of MoonLake Immunotherapeutics in the 4th quarter valued at approximately $338,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of MoonLake Immunotherapeutics by 17.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company’s stock valued at $2,287,000 after buying an additional 6,422 shares in the last quarter. Woodline Partners LP raised its position in shares of MoonLake Immunotherapeutics by 26.3% in the 4th quarter. Woodline Partners LP now owns 293,535 shares of the company’s stock valued at $15,895,000 after buying an additional 61,105 shares in the last quarter. Finally, Wexford Capital LP raised its position in shares of MoonLake Immunotherapeutics by 71.4% in the 4th quarter. Wexford Capital LP now owns 24,000 shares of the company’s stock valued at $1,300,000 after buying an additional 10,000 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.